The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. surprised health and privacy experts when he announced June 24 that his agency would launch a massive advertising campaign to encourage ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge announces a $300 million funding round.

Long-lasting insulin takes another step forward with latest clinical trial results Scripps researcher delivers findings for Lilly drug expected to request approval from FDA soon ...

A GLP-1 in pill form from Eli Lilly shows promising results for weight loss and Type 2 diabetes treatment in a trial. FDA approval is expected in 2026.

Eli Lilly’s $1.3 billion acquisition of Verve Therapeutics marks a strategic expansion into cardiovascular genetic medicine. The pharmaceutical giant paid a premium of about 113% over Verve’s ...

(RTTNews) - Eli Lilly and Co. (LLY) announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin ...

Eli Lilly is looking to approach regulatory approval of efsitora alfa (efsitora), its once-weekly insulin for type 2 diabetes.